Jul 08, 2019
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
Jul 03, 2019
Mucopolysaccharidosis (MPS) Treatment Market: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029
Jun 26, 2019
Global phenylketonuria treatment market is expected to grow with a healthy CAGR over the forecast period from 2019-2025
Jun 26, 2019
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019
Jun 21, 2019
BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Jun 18, 2019
BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia
Jun 05, 2019
BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA
Jun 04, 2019
BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
May 28, 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
May 28, 2019
BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
May 27, 2019
BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update
May 16, 2019
BioMarin to Participate in 2019 RBC Capital Markets Global Healthcare Conference on May 21 in New York City
May 08, 2019
BioMarin to Participate in Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas
May 06, 2019
European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older
Apr 25, 2019
BioMarin Announces First Quarter 2019 Financial Results
Apr 17, 2019
Forbes Names BioMarin 4th Best Midsize Employer in America
Mar 06, 2019
BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston
Mar 01, 2019
BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older
Feb 21, 2019
BioMarin Announces Full Year and Fourth Quarter 2018 Results
Feb 07, 2019
BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years